2013 RoundTable News

In the News

  • December 2013

    RoundTable Healthcare Partners Announces Sale of Aqua Pharmaceuticals Holdings, Inc. to Almirall S.A.

    LAKE FOREST, IL, December 17, 2013 – RoundTable Healthcare Partners (“RoundTable”), an operating-oriented private equity firm focused exclusively on the healthcare industry, announced today that it has entered into a definitive agreement to sell Aqua Pharmaceuticals Holdings, Inc. (“Aqua”) to Almirall S.A (“Almirall”) for up to $402.6 million in cash. The consideration includes $327.6 million of cash at closing plus up to $75 million of contingent payments. Almirall, headquartered in Barcelona, Spain, is a global pharmaceutical company committed to providing innovative products focused on the treatment of respiratory, dermatological, gastrointestinal and pain diseases. The closing is conditional on regulatory approval and other customary closing conditions.

  • July 2013

    RoundTable Healthcare Partners Acquires Santa Cruz Nutritionals from Levine Leichtman Capital Partners

    LAKE FOREST, IL, JULY 29, 2013 — RoundTable Healthcare Partners (“RoundTable”), an operating-oriented private equity firm focused exclusively on the healthcare industry, announced today that it has completed the acquisition of Santa Cruz Nutritionals (“SCN”, “Santa Cruz” or the “Company”) from Levine Leichtman Capital Partners (“LLCP”). SCN, founded in 1968, is a leading manufacturer of gummy vitamin, mineral, supplement (“VMS”) and other nutraceutical products in the United States. Financial terms of the transaction were not disclosed.

  • June 2013

    Renaissance and GLAXOSMITHKLINE Agree to a Transfer of Nine Products

    Acquisition Holdings, LLC (“Renaissance”) a RoundTable Healthcare Partners (“RoundTable”) portfolio company, and GlaxoSmithKline (LSE/NYSE: GSK) announced today that they have entered into an agreement giving Renaissance the rights in the USA to manufacture, market and sell six dermatology and three anti-viral products from GSK.

  • June 2013

    Aqua Pharmaceuticals Acquires Verdeso Foam

    West Chester, PA — June 4, 2013 – West Chester-based Aqua Pharmaceuticals today announces the acquisition of US rights to, and re-launch of Verdeso® (desonide) Foam, 0.05% from Stiefel, a GSK company (“GSK”). The emollient-based and ethanol-free Verdeso® Foam is the only low-potency corticosteroid foam indicated for the topical treatment of mild to moderate atopic dermatitis in patients 3 months of age and older. Aqua will assume control of all manufacturing and distribution, as well as promotion of the product through its own national dermatology-specialty sales force.

  • April 2013

    RoundTable Healthcare Partners and Argon Medical Devices Complete Acquisition of Angiotech Pharmaceuticals’ Interverntional Products Business

    LAKE FOREST, IL, APRIL 15, 2013 — RoundTable Healthcare Partners (“RoundTable”), an operating-oriented private equity firm focused exclusively on the healthcare industry, announced today that its portfolio company, Argon Medical Devices, Inc. (“Argon” or the “Company”), has completed the previously announced acquisition of the Interventional Products Business of Angiotech Pharmaceuticals, Inc. (“Angiotech”). The Interventional Products Business manufactures and markets disposable and re-usable biopsy products for the diagnosis of cancer, drainage catheter products, and vascular interventional products.

  • April 2013

    RoundTable Healthcare Partners Completes Portfolio Company Add-On Acquisition

    LAKE FOREST, IL, April 5, 2013 — RoundTable Healthcare Partners (“RoundTable”), an operating-oriented private equity firm focused exclusively on the healthcare industry, announced today that its portfolio company, Beaver-Visitec International, Inc. (“BVI”), a global leader of high-quality and world renowned brands for ophthalmic and specialty microsurgical procedures, has completed the acquisition of the ophthalmic assets from Odyssey Medical, Inc. (“Odyssey”), a leader in dry eye solutions. The financial terms of the transaction and RoundTable’s investment were not disclosed.

  • March 2013

    RoundTable Healthcare Partners and Argon Medical Devices to Acquire Angiotech Pharmaceuticals’ Interventional Products Business

    LAKE FOREST, IL, MARCH 25, 2013 — RoundTable Healthcare Partners (“RoundTable”), an operating-oriented private equity firm focused exclusively on the healthcare industry, announced today that its portfolio company, Argon Medical Devices, Inc. (“Argon” or the “Company”), entered into a definitive agreement to acquire the Interventional Products Business of Angiotech Pharmaceuticals, Inc. (“Angiotech”). The Interventional Products Business manufactures and markets disposable and re-usable biopsy products for the diagnosis of cancer, drainage catheter products, and vascular interventional products. The transaction is expected to be completed prior to the end of April 2013 subject to customary closing conditions.

  • March 2013

    RoundTable Announces 2nd Recipient of the Robert DeBaun Humanitarian Award

    RoundTable Healthcare Partners is pleased to announce the 2nd recipient of the Robert DeBaun Humanitarian Award. Sandy McEwen, nominee from Renaissance Pharma/DPT Labs San Antonio, emerged as the top choice from a group of distinguished candidates nominated by RoundTable portfolio companies.